{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:13:32Z","timestamp":1767212012427,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Aquaporin-4 immunoglobulin G (AQP4-IgG) antibody-positive neuromyelitis optica spectrum disorders (NMOSD) are frequently associated with other autoimmune disorders, including systemic lupus erythematosus (SLE). Eculizumab (ECU) is a highly effective long-term treatment for NMOSD. However, ECU is known to increase significantly the risk of infection with encapsulated bacteria and sepsis. Recently, increased insulin resistance (IR) in patients with NMOSD has been suggested. Type B IR (TBIR) is a rare autoimmune condition often accompanying or preceding SLE. TBIR has not yet been reported in NMOSD. Objective: To report an ECU-treated patient with AQP4-IgG-positive NMOSD who developed fatal septic complications after the emergence of TBIR. Methods: Description of the clinical course over a period of 8 years. Results: A female patient was diagnosed with NMOSD at the age of 16 years. A variety of disease-modifying drugs failed to achieve sufficient disease control, resulting in severe tetraparesis. Treatment with ECU was started 6 years after NMOSD diagnosis and stabilized the disease. The patient developed TBIR 8 months after initiation of ECU therapy. Following high-dose intravenous methylprednisolone therapy for a clinical relapse and three further courses of ECU, the patient was admitted with severe pneumonia caused by the encapsulated bacterium<jats:italic>Klebsiella pneumoniae<\/jats:italic>and hypoglycemia. Despite multimodal therapy, the patient died from sepsis-related multiorgan failure 18 months after initiation of ECU. Conclusions: TBIR should be considered as differential diagnosis in patients with NMOSD presenting with disturbed glucose metabolism, irrespective of the presence of SLE. More real-world data are needed on the risk\/benefit ratio of ECU treatment in patients who have co-existing autoimmune comorbidities that may compromise immune function. Strategies to mitigate the risk of serious infection in patients treated with ECU are discussed.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00415-023-12071-9","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:02:50Z","timestamp":1699956170000},"page":"2866-2870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome"],"prefix":"10.1007","volume":"271","author":[{"given":"S.","family":"Doubrovinskaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Korporal-Kuhnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jarius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"12071_CR1","unstructured":"European Medicines Agency. Soliris: EPAR - product information. First published: 01\/07\/2009. Last updated: 18\/08\/2023. Last accesse: 19\/08\/2023. URL: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf"},{"key":"12071_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00005792-200203000-00001","volume":"81","author":"E Arioglu","year":"2002","unstructured":"Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P (2002) Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 81:87\u2013100","journal-title":"Medicine (Baltimore)"},{"key":"12071_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1177\/1352458516671203","volume":"23","author":"N Borisow","year":"2017","unstructured":"Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke KD, Pache F, Ruprecht K, Havla J, Krumbholz M, Kumpfel T, Aktas O, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Weissert R, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Ruckriem L, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Hellwig K, on behalf of NEMOS (Neuromyelitis Optica Study Group) (2017) Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Mult Scler 23:1092\u20131103","journal-title":"Mult Scler"},{"key":"12071_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2478\/rir-2021-0019","volume":"2","author":"SCW Chan","year":"2021","unstructured":"Chan SCW, Lau CS (2021) Systemic lupus erythematosus and immunodeficiency. Rheumatol Immunol Res 2:131\u2013138","journal-title":"Rheumatol Immunol Res"},{"key":"12071_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jinf.2019.11.015","volume":"80","author":"PE Crew","year":"2020","unstructured":"Crew PE, McNamara L, Waldron PE, McCulley L, Christopher Jones S, Bersoff-Matcha SJ (2020) Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease. J Infect 80:350\u2013371","journal-title":"J Infect"},{"key":"12071_CR6","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","volume":"270","author":"S Jarius","year":"2023","unstructured":"Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K, Haussler V, Havla J, Hellwig K, Hummert MW, Kleiter I, Klotz L, Krumbholz M, Kumpfel T, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Tumani H, Wildemann B, Trebst C, Neuromyelitis Optica Study G (2023) Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis optica study group (NEMOS). Part I: diagnosis and differential diagnosis. J Neurol 270:3341\u20133368","journal-title":"J Neurol"},{"key":"12071_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kumpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134","journal-title":"J Neuroinflammation"},{"key":"12071_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B (2020) Neuromyelitis optica. Nat Rev Dis Prim 6:85","journal-title":"Nat Rev Dis Prim"},{"key":"12071_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","volume":"291","author":"S Jarius","year":"2010","unstructured":"Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger KP (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52\u201356","journal-title":"J Neurol Sci"},{"key":"12071_CR10","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"key":"12071_CR11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/B978-0-12-800100-4.00006-4","volume":"121","author":"M Levy","year":"2014","unstructured":"Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber MS, Stuve O (2014) Immunopathogenesis of neuromyelitis optica. Adv Immunol 121:213\u2013242","journal-title":"Adv Immunol"},{"key":"12071_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41577-022-00826-w","volume":"23","author":"MS Lionakis","year":"2023","unstructured":"Lionakis MS, Drummond RA, Hohl TM (2023) Immune responses to human fungal pathogens and therapeutic prospects. Nat Rev Immunol 23:433\u2013452","journal-title":"Nat Rev Immunol"},{"key":"12071_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12883-021-02198-5","volume":"21","author":"Z Maghbooli","year":"2021","unstructured":"Maghbooli Z, Naser Moghadasi A, Rezaeimanesh N, Omidifar A, Varzandi T, Sahraian MA (2021) The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder. BMC Neurol 21:167","journal-title":"BMC Neurol"},{"key":"12071_CR14","first-page":"337","volume":"64","author":"LM Martins","year":"2020","unstructured":"Martins LM, Fernandes VO, Carvalho MMD, Gadelha DD, Queiroz PC, Montenegro Junior RM (2020) Type B insulin resistance syndrome: a systematic review. Arch Endocrinol Metab 64:337\u2013348","journal-title":"Arch Endocrinol Metab"},{"key":"12071_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR (2017) High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep 66:734\u2013737","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"12071_CR16","doi-asserted-by":"publisher","first-page":"175628642311811","DOI":"10.1177\/17562864231181177","volume":"16","author":"I Nakashima","year":"2023","unstructured":"Nakashima I, Nakahara J, Yokote H, Manabe Y, Okamura K, Hasegawa K, Fujihara K (2023) Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. Ther Adv Neurol Disord 16:17562864231181176","journal-title":"Ther Adv Neurol Disord"},{"key":"12071_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-023-03630-x","volume":"118","author":"JI Nishimura","year":"2023","unstructured":"Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, Fukamizu Y, Akiyama H, Hayashi H, Nakano T, Maruyama S (2023) Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol 118:419\u2013431","journal-title":"Int J Hematol"},{"key":"12071_CR18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614\u2013625","journal-title":"N Engl J Med"},{"key":"12071_CR19","first-page":"664","volume":"28","author":"M Ringelstein","year":"2022","unstructured":"Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, \u00d6zalp SH, Lohmann L (2022) Eculizumab use in neuromyelitis optica spectrum disorders (NMOSD): real-world evidence from Germany and Austria (NEMOS). Mult Scler J 28:664\u2013666","journal-title":"Mult Scler J"},{"key":"12071_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1628466","volume":"42","author":"T Sawada","year":"2019","unstructured":"Sawada T, Fujimori D, Yamamoto Y (2019) Systemic lupus erythematosus and immunodeficiency. Immunol Med 42:1\u20139","journal-title":"Immunol Med"},{"key":"12071_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Socie","year":"2019","unstructured":"Socie G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185:297\u2013310","journal-title":"Br J Haematol"},{"key":"12071_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MED.0000000000000263","volume":"23","author":"DL Willard","year":"2016","unstructured":"Willard DL, Stevenson M, Steenkamp D (2016) Type B insulin resistance syndrome. Curr Opin Endocrinol Diabetes Obes 23:318\u2013323","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"12071_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMOD (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-12071-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T23:47:02Z","timestamp":1730504822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-12071-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["12071"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-12071-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"23 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest with regard to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"A legally authorized representative gave written informed consent to the reporting of the patient`s clinical history.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}